| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 |
| filingDate |
2011-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c1a8fe78d58675a191a6589d337f219
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7c7c9abcbb5f477726bd14bbf0d3668
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_441781c610c2c613fbd6904195c6040d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48cfb99781deec67cd8a980391caf90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8cb49e6c5bc4ced9f4e8b29705cdc74 |
| publicationDate |
2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011213736-A |
| titleOfInvention |
Pharmaceutical formulations containing levothyroxine sodium |
| abstract |
The present invention provides a stable pharmaceutical formulation of levothyroxine sodium useful for the treatment of thyroid hormone disorders in mammals including humans. The present invention provides (a) an effective amount of levothyroxine sodium, (b) a microparticle having an average particle size of less than 125 μm and present in an amount of 60-85% w / w based on the total weight of the formulation. A stable pharmaceutical formulation is provided comprising crystalline cellulose and (c) pregelatinized starch present in an amount of 5-30% w / w based on the total weight of the formulation. Moreover, the manufacturing method of this prescription is provided. [Selection figure] None |
| priorityDate |
2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |